BG101607A - Dihydropyrimdines and uses thereof - Google Patents

Dihydropyrimdines and uses thereof

Info

Publication number
BG101607A
BG101607A BG101607A BG10160797A BG101607A BG 101607 A BG101607 A BG 101607A BG 101607 A BG101607 A BG 101607A BG 10160797 A BG10160797 A BG 10160797A BG 101607 A BG101607 A BG 101607A
Authority
BG
Bulgaria
Prior art keywords
compounds
relaxinglower
prosthetichyperplasia
loweringintraocular
beuseful
Prior art date
Application number
BG101607A
Other languages
Bulgarian (bg)
English (en)
Inventor
Dhanapalan Nagarathnam
George Chiu
Murali Dhar
Wai Wong
Mohammad Marzabadi
Charles Gluchowski
Shou Miao
Bharat Ladu
Original Assignee
Synaptic Pharmaceutical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synaptic Pharmaceutical Corporation filed Critical Synaptic Pharmaceutical Corporation
Publication of BG101607A publication Critical patent/BG101607A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
BG101607A 1994-11-16 1997-06-12 Dihydropyrimdines and uses thereof BG101607A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34061194A 1994-11-16 1994-11-16
PCT/US1995/015025 WO1996014846A1 (en) 1994-11-16 1995-11-16 Dihydropyrimidines and uses thereof

Publications (1)

Publication Number Publication Date
BG101607A true BG101607A (en) 1998-02-27

Family

ID=23334169

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101607A BG101607A (en) 1994-11-16 1997-06-12 Dihydropyrimdines and uses thereof

Country Status (24)

Country Link
US (2) US5942517A (fi)
EP (1) EP0790826A4 (fi)
JP (1) JP3200070B2 (fi)
KR (1) KR970706823A (fi)
CN (1) CN1173132A (fi)
AR (1) AR005238A1 (fi)
AU (1) AU714640B2 (fi)
BG (1) BG101607A (fi)
BR (1) BR9509700A (fi)
CA (1) CA2205384C (fi)
CO (1) CO4950529A1 (fi)
CZ (1) CZ151297A3 (fi)
EE (1) EE9700209A (fi)
FI (1) FI972087A (fi)
HU (1) HUT77941A (fi)
IS (1) IS4481A (fi)
MD (1) MD970227A (fi)
MX (1) MX9703518A (fi)
NO (1) NO972236L (fi)
NZ (1) NZ297278A (fi)
PL (1) PL320263A1 (fi)
SK (1) SK60097A3 (fi)
WO (1) WO1996014846A1 (fi)
YU (1) YU60696A (fi)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL320263A1 (en) 1994-11-16 1997-09-15 Synaptic Pharma Corp Dihydropyrimidines and their application
US6268369B1 (en) 1994-11-16 2001-07-31 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US5661163A (en) 1995-06-07 1997-08-26 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
US6228861B1 (en) 1995-11-16 2001-05-08 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
AU727972B2 (en) * 1996-05-16 2001-01-04 H. Lundbeck A/S Dihydropyrimidines and uses thereof
US6214832B1 (en) 1997-06-18 2001-04-10 Merck & Co., Inc. Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists
US6057350A (en) * 1997-06-18 2000-05-02 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
WO1998057641A1 (en) * 1997-06-18 1998-12-23 Merck & Co., Inc. ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
US6143750A (en) * 1997-06-18 2000-11-07 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6376503B1 (en) 1997-06-18 2002-04-23 Merck & Co., Inc Alpha 1a adrenergic receptor antagonists
WO1998057940A1 (en) * 1997-06-18 1998-12-23 Synaptic Pharmaceutical Corporation Heterocyclic substituted piperidines and uses thereof
US6037354A (en) * 1997-06-18 2000-03-14 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6080760A (en) * 1997-06-18 2000-06-27 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
US6271234B1 (en) 1997-08-01 2001-08-07 Recordati S.A., Chemical And Pharmaceutical Company 1,4-disubstituted piperazines
CA2297889A1 (en) * 1997-08-05 1999-02-18 Norihiro Ikemoto Alpha 1a adrenergic receptor antagonist
US6207444B1 (en) 1997-08-05 2001-03-27 Merck & Co., Inc. Enzymatic process of making alpha 1a adrenergic receptor antagonists using protease
WO1999048530A1 (en) * 1998-03-23 1999-09-30 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
AU5234899A (en) * 1998-07-30 2000-02-21 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6268377B1 (en) 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
WO2000025782A1 (en) 1998-10-29 2000-05-11 Merck & Co., Inc. Dihydropyridinones and pyrrolinones useful as alpha 1a adrenoceptor antagonists
US6228870B1 (en) 1998-11-10 2001-05-08 Merck & Co., Inc. Oxazolidinones useful as alpha 1a adrenoceptor antagonists
US6319932B1 (en) 1998-11-10 2001-11-20 Merck & Co., Inc. Oxazolidinones useful as alpha 1A adrenoceptor antagonists
WO2000029386A1 (en) * 1998-11-12 2000-05-25 Merck & Co., Inc. Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
GB2344821A (en) 1998-12-17 2000-06-21 Merck & Co Inc Crystalline pharmaceutically acceptable salt of an oxazolidinone derivative
US6274585B1 (en) * 1998-12-23 2001-08-14 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6680323B2 (en) * 1998-12-23 2004-01-20 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
AU2386800A (en) * 1998-12-23 2000-07-12 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
GB2346142A (en) * 1999-01-26 2000-08-02 Merck & Co Inc Pyrimidinones useful for treating benign prostatic hyperplasia
EP1193259A4 (en) 1999-06-23 2003-01-29 Ajinomoto Kk dihydropyrimidine
GB2355456A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
GB2355263A (en) 1999-09-30 2001-04-18 Merck & Co Inc Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
GB2355457A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists
GB2355264A (en) 1999-09-30 2001-04-18 Merck & Co Inc Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists
US6720324B2 (en) * 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
WO2002006245A1 (en) * 2000-07-05 2002-01-24 Synaptic Pharmarceutical Corporation Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof
US6809102B2 (en) 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
WO2003006439A1 (en) 2001-07-13 2003-01-23 Astrazeneca Uk Limited Preparation of aminopyrimidine compounds
DK1578731T3 (da) 2002-12-16 2010-02-15 Astrazeneca Uk Ltd Fremgangsmåde til fremstilling af pyrimidinforbindelser
WO2005007124A2 (en) 2003-07-23 2005-01-27 Bristol-Myers Squibb Company Substituted dihydropyrimidine inhibitors of calcium channel function
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
CA2720312A1 (en) * 2004-01-30 2005-08-18 Euro-Celtique S.A. Methods for making 4-tetrazolyl-4-phenylpiperidine compounds
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
WO2007101213A2 (en) * 2006-02-28 2007-09-07 Kalypsys, Inc. Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors
CL2007002958A1 (es) * 2006-10-12 2008-05-09 Epix Delaware Inc Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr
KR20100102646A (ko) 2007-12-11 2010-09-24 가부시키가이샤 사이토파스파인더 카르복스아미드 화합물 및 케모카인 수용체 길항제로서의 이의 용도
EA027324B1 (ru) 2011-11-11 2017-07-31 Пфайзер Инк. 2-тиопиримидиноны
PE20180503A1 (es) 2015-05-05 2018-03-09 Pfizer 2-tiopirimidinonas
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5659778A (en) 1979-10-23 1981-05-23 Showa Denko Kk Dimethylthienopyrimidione derivative
US4438117A (en) 1980-09-03 1984-03-20 E. I. Du Pont De Nemours And Company 2-Substituted thio-4,5-diarylpyrimidines
US4683234A (en) 1984-05-19 1987-07-28 Suntory Limited 2,6-Dimethyl-3N,5-disubstituted-4-(substituted phenyl)3,4-dihydropyrimidine compounds and a method for treating disorders of cardiocircular system
US4684653A (en) * 1985-03-08 1987-08-04 The Trustees Of Princeton University Pyrido(2,3-d)pyrimidine derivatives
US4728652A (en) 1985-05-20 1988-03-01 E. R. Squibb & Sons, Inc. 2-substituted thio or oxy-4-aryl or heterocyclo-5-carboxy-1,4-dihydropyrimidines, composition containing them, and method of using them to reduce blood pressure
US5202330A (en) * 1985-06-03 1993-04-13 E. R. Squibb & Sons, Inc. 2-thio or oxo-4-aryl or heterocyclo-1,5(2H)-pyrimidinedicarboxylic acid diesters and 3-acyl-5-pyrimidinecarboxylic acids and esters
HUT42077A (en) 1985-06-03 1987-06-29 Squibb & Sons Inc Process for producing diesters of 2-tioxo- or 2-oxo-pyrimidine-1,5-dicarboxylic acid and 1-acyl-pyrimidine-5-carboxylic acids and esters
JPS6287574A (ja) 1985-10-14 1987-04-22 Suntory Ltd 新規なｎ置換３，４−ジヒドロピリミジン−２−オン誘導体、その製造法及び循環器系疾患治療剤
US4689414A (en) * 1986-02-24 1987-08-25 E. R. Squibb & Sons, Inc. 2-(substituted imino)-6-aryl-3,6-dihydro-4-substituted-1,5(2H)-pyrimidinecarboxylic acids and analogs
US4684656A (en) 1986-03-14 1987-08-04 E. R. Squibb & Sons, Inc. 1,2,3,4-tetrahydro-6-substituted-4-aryl-3-(substituted sulfonyl)-2-thioxo(or oxo)-5-pyrimidinecarboxylic acids and esters and method of using them to lower blood pressure
IL81800A0 (en) 1986-03-14 1987-10-20 Squibb & Sons Inc 1,2,3,4-tetrahydro-6-substituted-4-aryl(or heterocyclo)-3-((substituted amino)carbonyl)-2-thioxo(or oxo)-5-pyrimidine-carboxylic acids and esters and pharmaceutical compositions containing the same
US4855301A (en) * 1986-10-09 1989-08-08 E. R. Squibb & Sons, Inc. 1,2,3,4-Tetrahydro-6-substituted-4-aryl(or heterocyclo)-3-((substituted amino)carbonyl)-2-thioxo (or oxo)-5-pyrimidinecarboxylic acids and esters
US4684655A (en) 1986-03-14 1987-08-04 E. R. Squibb & Sons, Inc. 1,2,3,4-tetrahydro-6-substituted-4-aryl-3-substituted-2-thioxo(or oxo)-5-pyrimidinecarboxylic acids and esters and use thereof to lower blood pressure
CA1275410C (en) * 1986-03-14 1990-10-23 Karnail S. Atwal 1,2,3,4-tetrahydro-6-substituted-4-aryl(or heterocyclo) -3-substituted-2-thioxo(or oxo)-5- pyrimidinecarboxylic acids and esters
US4703120A (en) 1986-04-28 1987-10-27 Ortho Pharmaceutical Corporation Furo(3,4-d)pyrimidine-2,4-dione derivatives and intermediates thereof
US4902796A (en) * 1986-10-20 1990-02-20 The Trustees Of Princeton University 6-alkenyl and ethynyl derivatives of 2-amino-4-hydroxypyrido[2,3-d]pyrimidines
FR2610625B1 (fr) * 1987-02-10 1989-06-30 Inst Organicheskogo Sinteza Ak 2-oxo-4-(2'-difluoromethylthiophenyl)5-methoxycarbonyl-6-methyl-1,2,3,4-tetrahydropyrimidine
JPS63208580A (ja) 1987-02-21 1988-08-30 Suntory Ltd Ｎ置換３，４−ジヒドロピリミジン誘導体および循環器系疾患治療剤
JP2830008B2 (ja) * 1988-04-01 1998-12-02 武田薬品工業株式会社 縮合ピリミジン誘導体
US5149810A (en) 1988-04-22 1992-09-22 Imperial Chemical Industries Plc Pyrimidine compounds
US4882334A (en) * 1988-05-25 1989-11-21 The Trustees Of Princeton University N-(5,6,7,8-tetrahydropyrido]2,3-d]pyrimidin-6-ylethl-thineyl-and furylcarbonyl)-glutamic acid derivatives
GB8906168D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
CA2016465A1 (en) * 1989-06-02 1990-12-02 Zola Phillip Horovitz Method for preventing or treating anxiety employing a calcium channel blocker
EP0459666B1 (en) * 1990-05-31 1994-11-09 Pfizer Inc. Medicaments against impotence
EP0459568A3 (en) 1990-05-31 1992-09-30 Merck Sharp & Dohme Ltd. Substituted oxadiazoles and thiadiazoles for use in the treatment of glaucoma and novel compounds having such use
US5166148A (en) * 1990-07-09 1992-11-24 The Du Pont Merck Pharmaceutical Company 2-amino-1,4-dihydropyridine derivatives with calcium agonist and alpha1 -antagonist activity
JPH06507392A (ja) * 1991-02-26 1994-08-25 エイアールシー　１，インコーポレイテッド 交感神経性の持続性疼痛の治療のための組成物および方法
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5403847A (en) * 1992-11-13 1995-04-04 Synaptic Pharmaceutical Corporation Use of α1C specific compounds to treat benign prostatic hyperlasia
IL109220A0 (en) * 1993-04-05 1994-07-31 Synaptic Pharma Corp Dihydropyridines and new uses thereof
DE4313690A1 (de) * 1993-04-27 1994-11-03 Bayer Ag Kondensierte Chinolyl-dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln
DE4313692A1 (de) * 1993-04-27 1994-11-03 Bayer Ag 3-Chinolyl substituierte Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln
DE4313693A1 (de) * 1993-04-27 1994-11-03 Bayer Ag 2-Amino-4-chinolin-dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
NZ264063A (en) 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
US5521189A (en) 1994-05-06 1996-05-28 The University Of Nc At Ch Methods of treating pneumocystis carinii pneumonia
PL320263A1 (en) 1994-11-16 1997-09-15 Synaptic Pharma Corp Dihydropyrimidines and their application
US5594141A (en) 1994-11-23 1997-01-14 Neurogen Corporation Certain aminomethyl biphenyl, aminomethyl phenyl pyridine and aminomethyl phenyl pyrimidine derivatives; novel dopamine receptor subtype selective ligands
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
AU727972B2 (en) 1996-05-16 2001-01-04 H. Lundbeck A/S Dihydropyrimidines and uses thereof
CA2297889A1 (en) 1997-08-05 1999-02-18 Norihiro Ikemoto Alpha 1a adrenergic receptor antagonist
WO1999048530A1 (en) 1998-03-23 1999-09-30 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia

Also Published As

Publication number Publication date
CA2205384A1 (en) 1996-05-23
JP3200070B2 (ja) 2001-08-20
HUT77941A (hu) 1998-12-28
NO972236D0 (no) 1997-05-15
US6248747B1 (en) 2001-06-19
JPH10510247A (ja) 1998-10-06
US5942517A (en) 1999-08-24
NO972236L (no) 1997-07-01
SK60097A3 (en) 1998-01-14
FI972087A (fi) 1997-07-14
EP0790826A4 (en) 1998-11-11
PL320263A1 (en) 1997-09-15
MX9703518A (es) 1997-08-30
EE9700209A (et) 1998-04-15
KR970706823A (ko) 1997-12-01
AU4239896A (en) 1996-06-06
FI972087A0 (fi) 1997-05-15
CN1173132A (zh) 1998-02-11
NZ297278A (en) 1999-06-29
CO4950529A1 (es) 2000-09-01
CA2205384C (en) 2004-06-29
EP0790826A1 (en) 1997-08-27
AR005238A1 (es) 1999-04-28
YU60696A (sh) 1998-12-23
BR9509700A (pt) 1998-11-03
IS4481A (is) 1997-05-12
MD970227A (ro) 1999-05-31
AU714640B2 (en) 2000-01-06
WO1996014846A1 (en) 1996-05-23
CZ151297A3 (cs) 1998-07-15

Similar Documents

Publication Publication Date Title
BG101607A (en) Dihydropyrimdines and uses thereof
WO1998051311A3 (en) Dihydropyrimidines and uses thereof
HK1026892A1 (en) Imidazole and imidazoline derivatives and uses thereof
WO2000015205A3 (en) Use of acetylcholinesterase inhibitors for the preparation of pharmaceutical compositions for the treatment of functional and/or organic pain syndromes
HUP0102300A3 (en) Use of diazepin derivatives for preparing medicines for treating diseases influenced by somatostatine receptor, and new compounds
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
EP0859637A4 (en) COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF WEIGHT PROBLEMS, INCLUDING OBESITY
MY137348A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
EP2298298A3 (en) Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
WO1999017755A3 (en) Medicaments
WO2000013650A3 (en) Neuroprotection
SG188700A1 (en) Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
WO2000012623A3 (en) Use of 5-th receptor antagonists for the treatment of parkinson's disease
CA2369626A1 (en) Use of cell membrane penetrating indigoid bisindole derivatives
AU4542996A (en) Combined therapeutical treatment of hyperproliferative pathologies
IL206566A0 (en) Use of an antagonist to the igs4 neuromedin receptor polypeptide for the preparation of a medicament for the treatment of a disease related to the expression or acitivity of the igs4 neuromedin receptor polypeptide
CA2311423A1 (en) Method for treating hyperlipidemia
WO2001079209A3 (en) Diazafluorenone il-8 antagonists
AU655958B2 (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
WO2004091646A3 (en) Use of slurp-1 for treating diseases related to acetylcholine receptors dysfunction
MD970254A (en) Use of melatonine for treatment of patients having a medicamental dependence
WO2000004012A8 (en) COMPOUNDS SPECIFIC FOR THE HUMAN α1d ADRENERGIC RECEPTOR AND USES THEREOF
EP1159970A3 (en) A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss, comprising a nicotine receptor partial agonist and an anti-obesity agent
HUP0100105A3 (en) Application of tnf antagonists as medicaments for treating septic diseases
BG106078A (en) Thio-oxindole derivatives